PTC Therapeutics, Inc.
In the published model solve dated 2026-Q2, anchored at $69.21, PTC Therapeutics, Inc. (PTCT) is priced for today's economics sustained for ~6.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed August 8, 2026 from SEC EDGAR filings.
• PTC Therapeutics now sells four rare-disease medicines and collects royalties on a fifth it does not sell, and the newest of them, Sephience for phenylketonuria, brought in 151.3 million dollars in the June quarter with 1,647 patients on commercial therapy worldwide [Source: Q2 2026 results release, July 30, 2026]. • The company has already sold much of its Evrysdi royalty to an outside buyer, which is why a large liability for the sale of future royalties sits on the balance sheet and why a
Is PTCT overvalued? See what's priced in →
338 institutional managers reported holding PTCT in 13F filings for the quarter ended 2026-03-31. 52 opened new positions that quarter. Held by BlackRock, Vanguard Group, Janus Henderson, among others. On the short side, 11.8M shares were sold short as of the 2026-06-15 count, about 14% of shares outstanding (7.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PTCT's share count grew 17.2% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PTCT over the trailing three years: 2023: 1 buy totaling $199k. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PTCT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -3.7% | -44.2% |
| 2023-10-27 | -20.5% | +48.9% |
| 2024-03-01 | +13.3% | +3.3% |
| 2024-04-26 | +13.3% | +7.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PTCT's latest 8-K filings: 2026-07-30 (items 2.02, 5.02, 7.01, 9.01); 2026-06-18 (items 1.01, 2.03, 3.02, 8.01, 9.01); 2026-06-16 (items 8.01, 9.01); 2026-06-09 (items 5.02, 9.01); 2026-06-05 (items 5.07).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 8, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.